Welcome to our dedicated page for TempraMed Tech news (Ticker: TMPTF), a resource for investors and traders seeking the latest updates and insights on TempraMed Tech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect TempraMed Tech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of TempraMed Tech's position in the market.
TempraMed (CSE: VIVI, FSE: 9DY; OTC: TMPTF) announced a strategic partnership with Stealth Health, a North American telemedicine platform for longevity and precision wellness. The agreement integrates TempraMed’s VIVI temperature-controlled medication protection products into Stealth Health’s direct-to-patient telemedicine clinic and its enterprise white-label network.
The partnership targets patients using temperature-sensitive medications such as hormones, peptides, GLP-1s, biologics and anti-aging treatments, leveraging TempraMed’s patented, battery-free, space-grade thermal insulation technology. According to TempraMed, Stealth Health’s MSO-based, HIPAA-compliant platform, operational across all 50 U.S. states, provides scalable B2C access and reinforces TempraMed’s strategy to commercialize through clinical and wellness channels, while potentially opening additional global distribution opportunities.
TempraMed Technologies (CSE: VIVI, OTCQB: TMPTF) announced that its common shares have been approved for trading on the OTCQB Venture Market and are now DTC eligible, enabling electronic settlement through the Depository Trust Company. Shares will continue trading on the CSE under VIVI.
According to TempraMed, the OTCQB uplisting and DTC eligibility are expected to enhance trading accessibility for U.S. investors, improve liquidity potential, and broaden visibility among retail and institutional investors. TempraMed develops patented, FDA-registered temperature-controlled medication storage solutions, including VIVI Cap and VIVI Epi, with operations across North America, Europe and Asia.